Ex Vivo Tumor Visualization and Resection Margin Assessment Using Topically Applied Fluorescent Imaging Agents

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorErasmus Medical Center

About this trial

This is a proof-of-principle study, that uses freshly resected human solid tumor specimens to assess the performance of topically applied fluorescent imaging agents for the detection of tumor tissue and close / tumor-positive resection margins ex vivo. Surgery will be performed in conformity with hospital protocol. The study will not interfere with the standard clinical care.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients with a biopsy-proven solid tumor, scheduled for surgery at the Erasmus Medical Center.

Signed and dated informed consent obtained before any study-related procedure is performed.

Disqualifiers

Terminated surgical procedure.

No fresh specimen available.

Participation in a clinical trial for which the patient receives another fluorophore perioperatively.

Trial design

Design model

Single group

Treatments tested in this trial

  • Topical application of a fluorescent imaging agent

    Drug

    The fluorescent imaging agent will be topically applied only onto the resection planes of the freshly resected tumor specimen. During incubation and after each washing steps, visible light and fluorescent overlay images will be acquired using a fluorescence sensitive camera system.

Treatment groups

200 Participants
are divided into 1 treatment group
Group A: Topical application of a fluorescent imaging agentExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Tumor-to-background ratio (TBR) of the fluorescence signal on the resection specimen surface and on 3-5 mm thick tissue slices.

TBR was calculated by drawing a region of interest (ROI) spanning the tumor, and another in adjacent (muscle) tissue using the imaging system's integrated software

Time frame
through study completion, up to 3 years

Secondary outcomes

1

Imaging agent fluorescence signal intensity on close / tumor-positive resection planes compared with (wide) tumor-negative resection planes, as confirmed by histopathology

Signal intensity was determined from a region of interest (ROI) drawn in close / tumor-positive resection planes as well as (wide) tumor-negative resection planes, and comparing them using the imaging system's integrated software.

Time frame
through study completion, up to 3 years
2

Difference in tumor-to-background ratio (TBR) between different imaging time windows

TBR was calculated for different imaging time windows, and compared.

Time frame
through study completion, up to 3 years
3

The concordance between the presence of tumor cells and fluorescence signal

Overlaying fluorescence images with corresponding H\&E slides

Time frame
through study completion, up to 3 years
4

Depth of the fluorescence signal on 4-μm tissue slides

Penetration depth of topically applied fluorescent imaging agents was determined from fluorescence images

Time frame
through study completion, up to 3 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.